Patients with MI discharged in 2012: switch pattern for dual antiplatelet therapy during the first 365 days after MI
| Drug treatment | Number of discharged patients | Number of patients switching | Median time (days) to switch | Number of patients switching to clopidogrel | Number of patients switching to ticagrelor | Number of patients switching to prasugrel |
|---|---|---|---|---|---|---|
| PCI-treated patients | ||||||
| Clopidogrel | 719 | 25 | 73 (44–119) | 0 | 18 | 7 |
| Ticagrelor | 2198 | 214 | 110 (62–209) | 210 | 0 | <5 |
| Prasugrel | 524 | 33 | 147 (90–230) | 29 | <5 | 0 |
| Clopidogrel without ASA | 74 | <5 | 83 (12–90) | 0 | <5 | <5 |
| Ticagrelor without ASA | 110 | 18 | 84 (57–210) | 18 | 0 | 0 |
| Prasugrel without ASA | 29 | <5 | 200 (149–310) | <5 | 0 | 0 |
| No P2Y12 antagonist only ASA | 118 | 29 | 49 (15–119) | 13 | 7 | 9 |
| No P2Y12 antagonist or ASA | 24 | 14 | 34 (14–136) | 8 | <5 | <5 |
| Non-PCI-treated patients | ||||||
| Clopidogrel | 635 | 14 | 148 (73–213) | 0 | 13 | <5 |
| Ticagrelor | 868 | 102 | 107 (49–208) | 102 | 0 | 0 |
| Prasugrel | 25 | <5 | 52 (52–52) | 0 | <5 | 0 |
| Clopidogrel without ASA | 161 | <5 | 44 (33–106) | 0 | <5 | 0 |
| Ticagrelor without ASA | 68 | 11 | 133 (108–154) | 10 | 0 | <5 |
| No P2Y12 antagonist only ASA | 765 | 83 | 77 (13–167) | 58 | 22 | <5 |
| No P2Y12 antagonist or ASA | 424 | 21 | 92 (55–178) | 16 | 5 | 0 |
ASA, acetyl salicylic acid; MI, myocardial infarction; PCI, percutaneous coronary intervention.